Epigenomics AG, (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today announced the successful identification of novel candidate biomarkers in lung cancer. This marks the completion of the first step in Epigenomics’ screening test R&D program for this fatal disease.
